S
Scott North
Researcher at Cross Cancer Institute
Publications - 134
Citations - 9299
Scott North is an academic researcher from Cross Cancer Institute. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 33, co-authored 120 publications receiving 8274 citations. Previous affiliations of Scott North include Cornell University & University of Alberta.
Papers
More filters
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi,Howard I. Scher,Arturo Molina,Christopher J. Logothetis,Kim N. Chi,Robert Jones,John Staffurth,Scott North,Nicholas J. Vogelzang,Fred Saad,Paul N. Mainwaring,S. J. Harland,Oscar B. Goodman,Cora N. Sternberg,Jinhui Li,Thian Kheoh,C. M. Haqq,Johann S. de Bono +17 more
TL;DR: It is confirmed that abiraterone acetate significantly prolongs overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel treatment.
Journal ArticleDOI
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
TL;DR: In this study of patients progressing after enzalutamide, treatment with abiraterone was associated with a modest response rate and brief duration of effect and may not preclude a response to abIRaterone.
Journal ArticleDOI
The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy
Toni K. Choueiri,Wanling Xie,Christian K. Kollmannsberger,Scott North,Jennifer J. Knox,J. Geoffrey Lampard,David F. McDermott,Brian I. Rini,Daniel Y.C. Heng +8 more
TL;DR: In this article, the authors retrospectively reviewed baseline characteristics and outcomes of 314 patients with anti-vascular endothelial growth factor therapy naive, metastatic renal cell carcinoma from United States and Canadian cancer centers to study the impact of cytoreductive nephrectomy on overall survival.
Journal ArticleDOI
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
Michael A. Carducci,Fred Saad,Per-Anders Abrahamsson,David P. Dearnaley,Claude Schulman,Scott North,Darryl J. Sleep,Jeffrey D. Isaacson,Joel B. Nelson +8 more
TL;DR: The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC).